FerroptoCure raises ¥9.6 billion in Series A funding to advance ferroptosis-controlled drug development, led by ANRI and others.

Sep 22, 2025•14 days ago

Amount Raised

¥9.6 Billion

Round Type

series a

TokyoBiotechnology

Investors

Japan Agency For Medical Research And DevelopmentJapan Science And Technology AgencyVision IncubateDiamond Medino CapitalTokyo University Of Science Innovation CapitalAnri

Description

On September 19, FerroptoCure announced that it has raised a total of ¥9.6 billion in a Series A round. The funding will support overseas clinical trials for its lead pipeline, FC-004, and expand its research capabilities. Key investors include ANRI, Tokyo University of Science Innovation Capital, and several others. The company aims to develop innovative therapies targeting cancer and neurodegenerative diseases.

Company Information

Company

FerroptoCure

Location

Tokyo, Tokyo, Japan

About

FerroptoCure is engaged in ferroptosis-controlled drug discovery, focusing on developing new drugs for cancer and neurodegenerative diseases. Founded in May 2022 based on research from Keio University, the company targets iron-dependent cell death known as ferroptosis. They aim to create a next-generation anti-cancer drug platform, with their lead pipeline FC-004 currently progressing in clinical trials. Their technology involves inhibiting the cystine/glutamate exchange transporter xCT to induce ferroptosis in cancer cells.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns